Toronto, Ontario--(Newsfile Corp. - March 21, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer and partner in a wide-range of leading-edge, proprietary diagnostic and medical device technologies, announced that its Board of Directors ("the Board") has initiated a review process to review, evaluate and explore a broad range of strategic initiatives and alternatives with the intent to maximize shareholder value.

VANCOUVER, BC, Feb. 6, 2024 /CNW/ - Trading resumes in:

Company To Resume Trading on Toronto Stock Exchange Venture (TSXV) on February 7, 2024

Toronto, Ontario--(Newsfile Corp. - December 5, 2023) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer and partner in a wide-range of leading-edge, proprietary diagnostic and medical device technologies, announces that a cease trade order has been issued by the Ontario Securities Commission for not filing the following documents by the periodic disclosure deadline:

VANCOUVER, BC, Dec. 5, 2023 /CNW/ - The following issues have been halted by CIRO

Company's DCA Solution Offers Robust Set of User and Medical Practitioner Features via an Android & iOS Mobile App and a Clinician Dashboard For Monitoring Patient's Cough

Toronto, Ontario--(Newsfile Corp. - November 2, 2023) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX) ("Therma" or the "Company"), developer and partner in a wide-range of leading-edge, proprietary diagnostic and medical device technologies, announced today the Company has opened its existing and new distribution channels for its Venowave device.

VANCOUVER, BC, Oct. 24, 2023 /CNW/ -

Toronto, Ontario--(Newsfile Corp. - September 29, 2023) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer and partner in a wide-range of leading-edge, proprietary diagnostic and medical device technologies, is pleased to announce that Mr. Eric Myung, CPA, CA, has taken on the role of CFO. Mr. Myung will assume his CFO role effective immediately.

Toronto, Ontario--(Newsfile Corp. - September 29, 2023) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer and partner in a wide-range of leading-edge, proprietary diagnostic and medical device technologies, announces that it has changed its auditors from HS & Partners LLP ("Former Auditor") to Zeifmans LLP ("Successor Auditor"). At the request of the Company, the Former Auditor was terminated as the auditor of the Company effective February 22, 2023, and the board of directors of the Company appointed the Successor Auditor as the Company's auditor effective February 22, 2023. The change of auditor has been approved by the Company's board of directors and its audit committee.

InStatin & InVixa Are Developing Novel Treatments for COVID-19, Asthma, and Chronic Obstructive Pulmonary Disease (COPD)

Toronto, Ontario--(Newsfile Corp. - September 13, 2023) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer and partner in a wide-range of leading-edge, proprietary diagnostic and medical device technologies, announced today the Company has signed Hero LifeCare (herolifecare.com) to be a U.S. distribution partner for marketing and selling the Venowave device.

Toronto, Ontario--(Newsfile Corp. - September 7, 2023) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer and partner in a wide-range of leading-edge, proprietary diagnostic and medical device technologies, announced today the Company has submitted an updated U.S. Food and Drug Administration (FDA) 510K application to correct the Venowave device's intended use, labeling and product description in order to better address the U.S. Centers for Medicare and Medicaid Services (CMS) application for permanent Current Procedural Terminology (CPT®) / Healthcare Common Procedure Coding System (HCPCS) codes.

Toronto, Ontario--(Newsfile Corp. - August 22, 2023) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer and partner in a wide-range of leading-edge, proprietary diagnostic and medical device technologies, announced today that the Company has heard back from the Centers for Medicare and Medicaid Services (CMS) on its application for the nine (9) unique permanent Current Procedural Terminology (CPT®) / Healthcare Common Procedure Coding System (HCPCS) codes.

Therma Bright Inc CEO Rob Fia discusses the imminent decision on permanent codes for Venowave, its compact, lightweight deep vein thrombosis (DVT) prevention device, with Proactive's Stephen Gunnion.

Toronto, Ontario--(Newsfile Corp. - August 4, 2023) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer and partner in a wide-range of leading-edge, proprietary diagnostic and medical device technologies, announced today that it expects a final decision regarding the issuance of the unique permanent Current Procedural Terminology (CPT®) / Healthcare Common Procedure Coding System (HCPCS) codes to be released by the Centers for Medicare and Medicaid Services (CMS) within the coming weeks.

Toronto, Ontario--(Newsfile Corp. - June 30, 2023) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer and partner in a wide-range of leading-edge, proprietary diagnostic and medical device technologies, announced that on May 31, 2023, representatives from Therma Bright Inc and the U.S. Department of Health and Human Services (DHHS) engaged in productive discussions regarding the significance and potential impact of securing unique permanent Current Procedural Terminology (CPT®) / Healthcare Common Procedure Coding System (HCPCS) codes for the innovative Venowave device. The final decision regarding the issuance of these unique CPT and HCPCS codes will be released by the Centers for Medicare and Medicaid Services (CMS) in August 2023.

VANCOUVER, BC, June 22, 2023 /CNW/ -

Company Sees Benefits For Healthcare Practitioners, Businesses and Governments To Better Collect, Capture And Analyze Critical Respiratory Data

Both Companies Anticipates Approval to Launch of Human Clinical Trials

Toronto, Ontario--(Newsfile Corp. - May 25, 2023) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer and partner in a wide-range of leading-edge, proprietary diagnostic and medical device technologies, is pleased to announce that the Company is working with its U.S distributor network on expanding sales of Venowave under the nine (9) temporary Current Procedural Terminology (CPT®) and Healthcare Common Procedure Coding System (HCPCS) codes issued by the Centers for U.S. Medicare and U.S. Medicaid Services for patient reimbursements.

Toronto, Ontario--(Newsfile Corp. - May 10, 2023) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer and investor in a wide-range of leading-edge, proprietary diagnostic and medical device technologies, is pleased to announce that the Company has established collaborations with several Tuberculosis (TB) medical care facilities to initiate the data collection and screening of active respiratory challenged patients.

Toronto, Ontario--(Newsfile Corp. - April 21, 2023) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma Bright" or the "Company"), developer and investor in a range of leading-edge, proprietary diagnostic and medical device technologies, is pleased to announce that further to its news releases of January 19 and March 6, 2023, relating to its acquisition of up to 25% of Inretio Inc., it has now paid the portion of the purchase price comprised of US$500,000 in Therma Bright shares, being 6,766,500 common shares of Therma Bright. In accordance with TSX Venture Exchange requirements, these shares were issued at a deemed price of CAD$0.10/share. The shares are subject to a hold period expiring August 1, 2023, in accordance with applicable securities laws and the policies of the TSX Venture Exchange. These issued shares, along with USD$250,000 in cash payments previously made to Inretio, increases Therma Bright's ownership interest in Inretio to 7.5%.

Toronto, Ontario--(Newsfile Corp. - April 14, 2023) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer and investor in a range of leading-edge, proprietary diagnostic and medical device technologies, is pleased to announce that the Company has successfully secured U.S. Medicare and Medicaid reimbursement through various payers. The reimbursement per pair of Venowave devices, under these temporary codes, ranged between $725-$1050 per patient. Therma Bright begins final stage in securing unique permanent Current Procedural Terminology (CPT®) / Healthcare Common Procedure Coding System (HCPCS) codes for the innovative Venowave device.

Toronto, Ontario--(Newsfile Corp. - March 23, 2023) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer and investor in a range of leading-edge, proprietary diagnostic and medical device technologies, is pleased to announce that the Company and AI4LYF are preparing to launch DCT, its digital cough data collection and screening smartphone application.

New Space Offers Advanced Development Capabilities for the PREVA (TM) Clot Removal Device for Ischemic Stroke Treatment

Dr. John Patton is recognized as a Leader in the Inhaled Formulation Solutions To Bring Industry Expertise To Innovative, Research-Based Pharmaceutical Firm

Toronto, Ontario--(Newsfile Corp. - February 23, 2023) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer and partner in a range of leading edge, proprietary diagnostic and medical device technologies, is pleased to provide an update on its partnership with Inretio Inc. ("Inretio"), a leading Israeli medical device startup developing a novel clot removal device for use in treating ischemic stroke patients.

Toronto, Ontario--(Newsfile Corp. - February 16, 2023) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma Bright" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce that it has finalized and signed the exclusive worldwide licensing rights to market and sell AI4LYF's Digital Cough Technology (DCT). DCT can accurately and almost instantaneously detect multiple respiratory diseases, including COVID-19, simply and efficiently through a smartphone app, anytime, anywhere. The exclusive license agreement also will allow Therma Bright to develop the DCT solution for other respiratory diseases, such as asthma, pneumonia, bronchiolitis, and chronic obstructive pulmonary disease.

Toronto, Ontario--(Newsfile Corp. - January 19, 2023) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma Bright" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce that it has signed a SPA (Share Purchase Agreement) with Inretio Ltd. ("Inretio") for its innovative protective blood clot retriever technology. Therma Bright has the right to invest up to USD $2,000,000 in cash and USD $500,000 in Therma Bright shares to earn up to 25% in Inretio Inc., subject to TSX Venture Exchange approval. The cash and shares are payable, at Therma's option, upon certain milestones being achieved by Inretio over time by the end of May 31, 2024. Therma Bright has made the first payment to Inretio totaling USD $200,000.

Toronto, Ontario--(Newsfile Corp. - December 21, 2022) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to provide a summary of activities and accomplishments achieved during 2022 as outlined below.

Toronto, Ontario--(Newsfile Corp. - December 1, 2022) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce that it has entered into an agreement to acquire an interest in a novel technology that utilizes inhaled statins for the treatment of respiratory conditions including asthma, chronic obstructive pulmonary disease ("COPD"), and acute lung inflammatory diseases including that caused by COVID-19 and other causes of acute respiratory distress syndrome (ARDS).

Toronto, Ontario--(Newsfile Corp. - November 17, 2022) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma Bright" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce that it has entered into a letter of intent ("LOI") with AI4LYF LLC ("AI4LYF") for the exclusive licensing rights for a digital cough-based diagnosis screening technology.

Toronto, Ontario--(Newsfile Corp. - October 27, 2022) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce that it has received new temporary PDAC (Pricing, Data Analysis and Coding) billing codes for its Venowave product giving Therma Bright immediate access to reimbursement through Medicare and Medicaid.

Toronto, Ontario--(Newsfile Corp. - September 20, 2022) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce that the initial order of its updated Venowave product has been sold to customers in the US by our exclusive distributor, DME Authority. Therma Bright is pleased to announce it has received payment towards this initial order.

Toronto, Ontario--(Newsfile Corp. - September 12, 2022) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, provides an update on it AcuVid™ COVID-19 Rapid Antigen Saliva Test's Emergency Use Authorization application with the U.S. Food and Drug Administration.

Toronto, Ontario--(Newsfile Corp. - August 4, 2022) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to provide the following update for Its AcuVid™ COVID-19 Rapid Antigen Saliva Test.

Toronto, Ontario--(Newsfile Corp. - June 23, 2022) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce the submission of its Health Canada application for the smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test for Point-of-Care Use (PoC). The HC application includes all the updated data from the Company's U.S. Food and Drug Administration's Emergency Use Authorization (EUA) application.

Toronto, Ontario--(Newsfile Corp. - June 10, 2022) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), developer of the smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive medical device technologies, announces that it has granted incentive stock options to certain directors, officers and consultants of the Company to purchase up to an aggregate of 1,475,000 common shares of the Company pursuant to the Company's share option plan. The options are exercisable for a period of three years at a price of $0.25 per share.

Toronto, Ontario--(Newsfile Corp. - June 2, 2022) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), developer of the smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive medical device technologies, is pleased to provide an update for the Company's AcuVid™ COVID-19 Rapid Antigen Saliva Test and its U.S. Food and Drug Administration's Emergency Use Authorization application process.

Toronto, Ontario--(Newsfile Corp. - May 10, 2022) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company, is pleased to announce that it will submit an application to Health Canada for review of the Company's AcuVid™ COVID-19 Rapid Antigen Saliva Test for detecting SARS CoV-2 virus in saliva.

Toronto, Ontario--(Newsfile Corp. - April 28, 2022) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company and developer of the AcuVid™ Covid-19 Rapid Antigen Saliva Test, is pleased to announce that the initial order of its updated Venowave product has been shipped to its US distributor, DME Authority, LLC, from Therma's Chinese contract manufacturer. As previously announced on December 16, 2021 the initial order consists of 2,500 units, each unit consists of 2 Venowave devices, of which 500 units have been shipped by air, with the balance being shipped by sea.

Toronto, Ontario--(Newsfile Corp. - March 29, 2022) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce the submission of its U.S. Food & Drug Administration's (FDA) Emergency Use Authorization (EUA) application for its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test for Point of Care (POC).

Toronto, Ontario--(Newsfile Corp. - February 24, 2022) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce the Company has been recognized in the 2022 TSX Venture 50 for top performing stocks, and ranked in the top three (3) for the Life Sciences sector.

Toronto, Ontario--(Newsfile Corp. - February 23, 2022) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce that on February 4, 2022 the U.S. Patent and Trademark Office allowed a U.S. patent application (US 15/787,599) which covers a device that can apply heat and antimicrobial treatment through a detachable applicator surface comprising copper or silver to provide heat conductivity and a source of antimicrobial agent. The device also includes a light source. This U.S. patent applies to both Therma Bright's InterceptCS™ Cold Sore Prevention Device and TherOZap™ Insect Bite Relief Device.

Toronto, Ontario--(Newsfile Corp. - February 18, 2022) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce that it has closed its previously announced private placement to institutional investors of its common shares ("Common Shares") (or Common Share equivalents) and warrants to purchase Common Shares ("Warrants") for gross proceeds of CAD$6 million (the "Private Placement"). Pursuant to the Private Placement, the Company issued 20,000,000 Common Shares and Warrants to purchase up to an aggregate of 20,000,000 Common Shares at a purchase price of CAD$0.30 per Common Share and associated Warrant. Each Warrant entitles the holder to purchase Common Shares at an exercise price of CAD$0.375 per Common Share at any time on or prior to February 18, 2027.

Toronto, Ontario--(Newsfile Corp. - February 16, 2022) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce that it has entered into a securities purchase agreement with institutional investors for a private placement of its common shares ("Common Shares") (or Common Share equivalents) and warrants to purchase Common Shares ("Warrants") for gross proceeds of CAD$6 million (the "Private Placement"). Pursuant to the Private Placement, the Company will issue 20,000,000 Common Shares (or Common Share equivalents) and Warrants to purchase up to an aggregate of 20,000,000 Common Shares at a purchase price of CAD$0.30 per Common Share and associated Warrant. Each Warrant will entitle the holder to purchase Common Shares at an exercise price of CAD$0.375 per Common Share for a period of five years following the issuance date.

Toronto, Ontario--(Newsfile Corp. - February 15, 2022) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce its AcuVid™ COVID-19 Rapid Antigen Saliva Test for Point of Care (PoC) has successfully exceeded U.S. Food & Drug Administration's (FDA) Emergency Use Authorization (EUA) requirements for both Positive Percent Agreement (PPA) and Negative Percent Agreement (NPA). The Company's management and product development teams are currently compiling the U.S. Clinical Performance Study results with all supplemental studies into one complete FDA EUA application for submission. This achievement places Therma Bright in a very unique leadership position as the first company in the COVID-19 diagnostic testing space to successfully complete a 15-minute rapid antigen saliva-based U.S. study.

Toronto, Ontario--(Newsfile Corp. - January 31, 2022) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, announced today that the Company has completed the U.S. Clinical Performance Study's subject recruitment effort and awaits final RT-PCR results to match against each test subject's AcuVid™ COVID-19 Rapid Antigen Saliva Test result. As stated in the January 20, 2022 release, once the clinical data has been tabulated, the final results will be filed with the U.S. Food & Drug Administration for Emergency Use Authorization (EUA) consideration.

Toronto, Ontario--(Newsfile Corp. - January 20, 2022) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, announced today that its U.S. Clinical Performance Study is still underway. Once the clinical data has been completed and tabulated, the final results will be reported to the marketplace and the U.S. Food & Drug Administration for Emergence Use Authorization consideration.

Toronto, Ontario--(Newsfile Corp. - December 16, 2021) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to confirm that antibodies incorporated in its AcuVid™ COVID-19 Rapid Antigen Saliva Test have been tested and can successfully detect the new, highly transmissible COVID-19 Omicron B.1.1.529 variant.

Agreement with Contract Manufacturer Provides for Production of 500,000 AcuVid(TM) Tests Per Week

The Innovative Hot & Cold Contrast Therapy Device for Relief of Chronic Pain

Toronto, Ontario--(Newsfile Corp. - November 12, 2021) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce that it will begin its U.S. clinical performance study with the receipt of Institutional Review Board's (IRB) conditional approval late yesterday, Thursday, November 11, 2021.

Toronto, Ontario--(Newsfile Corp. - October 28, 2021) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, announces that Therma has been in communication with the FDA over the intervening period since the initial submission of its AcuVid™ COVID-19 Rapid Antigen Saliva Test. Therma has responded to the FDA questions and suggestions and has completed additional documentation and lab tests as required by the FDA.

Toronto, Ontario--(Newsfile Corp. - October 4, 2021) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company and developer of the AcuVid™ Covid-19 Rapid Antigen Saliva Test, provides the following update for its AcuVidTM Covid-19 Rapid Saliva Antigen Test.

Provides Update on FDA-EUA Application Process

Toronto, Ontario--(Newsfile Corp. - September 1, 2021) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to provide an update on its AcuVid™ Saliva Test with the US Food & Drug Administration's Emergency Use Authorization (EUA) application.

Toronto, Ontario--(Newsfile Corp. - August 12, 2021) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), developer of its 'smart-enabled' AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, advises that it has entered into a securities for services agreement with a consultant to provide services related to the development and opening up of new retail distribution channels/outlets for the Company and the development and opening up of new value-added resellers for the Company. In consideration for its services, Therma Bright will issue up to 800,000 warrants, in tranches, upon certain milestones being met. The Company has now received TSXV approval to this agreement and accordingly has issued 700,000 warrants, with each warrant being exercisable for one common share for two years at a price of $0.46. All of these securities are subject to a hold period expiring December 13, 2021 in accordance with applicable securities laws and the policies of the TSXV.

Company To Begin Embedding Solution Onto Each 15-Minute COVID-19 Rapid Antigen Test Cartridge

Toronto, Ontario--(Newsfile Corp. - July 29, 2021) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce that it has applied for OTCQB listing and full eligibility through the Depository Trust Company (DTC), a subsidiary of the Depository Trust & Clearing Corp., which manages the electronic clearing and settlement of publicly traded companies in the United States.

VANCOUVER, BC, July 22, 2021 /CNW/ - Trading resumes in:

Toronto, Ontario--(Newsfile Corp. - July 22, 2021) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to provide an update on its AcuVid™ COVID-19 Rapid Antigen Saliva Test and awaits an official response from the U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) review for its COVID-19 rapid antigen test application.

VANCOUVER, BC, July 22, 2021 /CNW/ - The following issues have been halted by IIROC:

Toronto, Ontario--(Newsfile Corp. - July 8, 2021) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce the completion and validation that its AcuVid™ COVID-19 Rapid Antigen Saliva Test successfully detected the highly contagious, fast moving COVID-19 Delta B.1.617.2 variant. The AcuVid™ / Delta variant study was completed at the Company's Brazilian clinical study partner's lab location at the Federal University of Minas Gerais.

Toronto, Ontario--(Newsfile Corp. - June 28, 2021) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce that it has secured an exclusive US distributor, a Nashville, Tennessee based organization, DME Authority for Therma's patented FDA approved Venowave, a lightweight Deep Vein Thrombosis (DVT) prophylaxis device. The multi-year agreement provides Therma Bright with a $10 Million annual minimum purchase commitment, with the initial signing order of 5,000 units coming at a time when competitive mobile DVT prevention devices of the same product category are scarce, on back-order, or indefinitely unavailable in the US due to chip manufacturer shortages similarly affecting many other major industries.

Toronto, Ontario--(Newsfile Corp. - June 24, 2021) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce that it will test the SARS-CoV-2 (COVID-19) Delta variant, first detected in India, with its AcuVid™ antigen saliva test. Governments and global health experts have expressed deep concerns that the highly contagious, fast spreading Delta variant will add to a new wave of COVID-19 viral infections globally later this summer and fall. The Delta variant has already become the dominant version of the SARS-CoV-2 (COVID-19) virus in the United Kingdom and has been detected in at least 74 other countries worldwide,

Toronto, Ontario--(Newsfile Corp. - June 17, 2021) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), developer of the AcuVid™ COVID-19 Rapid Antigen Saliva Test and a progressive medical device technology company, is pleased to provide an update on the exceptional performance of its AcuVid™ COVID-19 Rapid Antigen Saliva Test's Brazilian Clinical Study, conducted in Minas Gerais, Brazil.

Company advances final validation efforts of its AcuVid(TM) COVID-19 Rapid Antigen Saliva Test

K-One MediTech To Begin Production of CE approved 15-Minute Antigen Test Solution

Toronto, Ontario--(Newsfile Corp. - May 6, 2021) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), developer of the AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce that it has entered into a distribution agreement to white label and distribute a 15-minute rapid COVID-19 antibody test for detecting IgG and IgM antibodies against SARS-CoV-2. The new product will be branded Therma Bright's AcuVid™ COVID-19 Rapid Antibody Test. This pinprick antibody blood test (i.e. serology test) uses a small amount of blood and has a 96.6% sensitivity for detecting antibodies of SARS-CoV-2 in those individuals currently infected with the virus or who have previously been infected, but went undiagnosed or were unaware of their infection. It will also aid in determining antibodies generated by those who have received a COVID-19 vaccine.

VANCOUVER, BC, April 28, 2021 /CNW/ - Trading resumes in:

Silicon Valley tech firm brings encrypted solution for tracking Canadian developer's 15-minute Covid19 rapid antigen test for point of care, and then at-home testing

VANCOUVER, BC, April 28, 2021 /CNW/ - The following issues have been halted by IIROC:

Toronto, Ontario--(Newsfile Corp. - April 22, 2021) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), developer of the AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce successful preliminary results with its AcuVid™ COVID-19 Rapid Antigen Saliva Test to detect the SARS-CoV-2 Variants of Concern ("VOC") that are rapidly spreading across Canada and many other countries; specifically the Brazilian P.1 and P.2 and the UK B.1.1.7 variants. The results were obtained in the performance study currently being conducted in Brazil at the Federal University of Minas Gerais (UFMG).

New global distribution partner McWilliams Collective secures test kit order from European client

Toronto, Ontario--(Newsfile Corp. - April 13, 2021) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), developer of the AcuVid™ Covid-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce that an initial phase of the Brazilian study of the AcuVid™ saliva-based rapid antigen test has been completed. Dr. Ricardo Fujiwara, from the Federal University of Minas Gerais, stated that, "The AcuVid™ initial results confirm the sensitivity and specificity results achieved in Therma's development studies of the AcuVid™ test against the SARS-CoV-2 first identified strain which originated from Wuhan, China."

Toronto, Ontario--(Newsfile Corp. - March 25, 2021) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), developer of the AcuVid™ Covid-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce that it has received IRB approval and subsequently submitted to Health Canada seeking approval to conduct a clinical performance study of its AcuVidTM Covid-19 Rapid Saliva-based Antigen Test.

Toronto, Ontario--(Newsfile Corp. - March 24, 2021) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), developer of the AcuVidTM COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, announces that it has entered into business agreement with Ridge Global, the consultancy founded by Governor Tom Ridge, the first U.S. Secretary of Homeland Security. The agreement focuses on supporting the Company's reach across the United States and Global marketplace business community along with extending policy advisory services in the U.S.

Toronto, Ontario--(Newsfile Corp. - March 18, 2021) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company, is pleased to announce that it has entered into an agreement with Safetest Diagnósticos("Safetest") of Brazil in partnership with the Federal University of Minas Gerais to conduct a clinical performance study of its AcuVidTM COVID-19 Rapid Saliva-based Antigen Test.

Toronto, Ontario--(Newsfile Corp. - March 11, 2021) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company, is pleased to announce that it has submitted an application to an independent Research Ethics Board ("REB") for approval to conduct a clinical study with the Company's AcuVid TM rapid antigen test for detecting SARS CoV-2 virus in saliva. Approval is expected within a week, at which point Therma will submit a complete package, including the REB review, to Health Canada to conduct the clinical trial.

Toronto, Ontario--(Newsfile Corp. - February 26, 2021) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company, is pleased to announce that it has entered into an agreement with a COVID-19 testing site located in the Greater Toronto Area to conduct a clinical study with the Company's AcuVid TM rapid antigen test for detecting SARS-CoV-2 virus in saliva.

VANCOUVER, BC, Feb. 26, 2021 /CNW/ - Trading resumes in:

VANCOUVER, BC, Feb. 26, 2021 /CNW/ - The following issues have been halted by IIROC:

Toronto, Ontario--(Newsfile Corp. - January 29, 2021) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company, is pleased to announce that in the past month, investors have exercised a total of 7,582,500 warrants and options to add $1,171,875 to the Company's treasury. With the addition of the $300,000, as previously reported in the press release on December 24th, 2020, the Company has added a total of $1,471,875 to the Company's treasury through the exercise of warrants and options in the last month. These funds will be used to advance the development of the Company's COVID-19 saliva-based rapid antigen test, SCV2, and for general working capital.

Toronto, Ontario--(Newsfile Corp. - January 25, 2021) - Therma Bright Inc. (TSXV: THRM) ("Therma Bright" or the "Company"), a progressive medical device technology company announces that it has taken 100% control of the research and development, regulatory, manufacturing and commercialization of its saliva-based rapid antigen test. As a result, Therma Bright will retain 100% of all future revenue and profits from the sale of the saliva-based rapid antigen test. Therma Bright previously announced on November 4, 2020, that it would retain 50% of the revenue and profit from the sale of its rapid antigen test through Torion Biosciences Inc. ("Torion"). Therma Bright will no longer pursue that arrangement with Torion Biosciences Inc., with 100% of the future economic benefit now flowing directly to Therma Bright Inc. In addition, Therma Bright will create a new trademark name for its saliva-based rapid antigen test, temporarily called SCV2, until a new name is protected.

Toronto, Ontario--(Newsfile Corp. - January 18, 2021) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company, is pleased to announce that the most recent results achieved with nanoComposix using banked human saliva samples and utilizing a CoviSafe™ prototype device indicate a test sensitivity of 86% and a specificity of 100% for Therma's CoviSafe™ rapid antigen test for detecting SARS-CoV-2 virus in saliva.

VANCOUVER, BC, Jan. 18, 2021 /CNW/ - Trading resumes in:

VANCOUVER, BC, Jan. 18, 2021 /CNW/ - The following issues have been halted by IIROC:

Toronto, Ontario--(Newsfile Corp. - January 15, 2021) -  Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company, is pleased to announce the appointment of Ian Levine to the advisory board to assist with future scaling for the manufacture of CoviSafe™.

Toronto, Ontario--(Newsfile Corp. - December 24, 2020) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company, announces that it has engaged Barwicki Investor Relations to provide investor relations services to the Company. Founded by Andrew Barwicki in 2006, Barwicki Investor Relations is a full service investor relations firm representing publicly traded companies and pre-IPO companies. Andrew Barwicki has 25+ years experience in finance, investor relations, investment banking and marketing. Mr. Barwicki worked in numerous industries and represented public companies in various sectors, including consumer products, regional and national banks, gold, silver and copper exploration and mining companies, entertainment, media, advertising, technology, distribution/logistics, biotech/pharmaceutical, energy/oil drilling and financial services. Pursuant to the terms of its agreement with Barwicki Investor Relations, the Company will pay $3,000 per month. The agreement is a month-to-month contract and may be terminated at any time upon written notice.

Toronto, Ontario--(Newsfile Corp. - December 7, 2020) -  Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company, is pleased to announce the preliminary results achieved during the feasibility studies indicate a test sensitivity of 80% and a specificity of over 90% for Therma's CoviSafe™ rapid test for detecting SARS-CoV-2 in saliva.

Therma Bright Investigates Spinoff of its Consumer Products

Successful Completion of the feasibility Studies followed by engagement of nanoComposix to accelerate the development of CoviSafe(TM)

Toronto, Ontario--(Newsfile Corp. - October 8, 2020) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company, and its co-development partner, Orpheus Medica Inc. ("Orpheus") are pleased to announce the recent award of a Mitacs Elevate research internship program . The project proposal has been peer-reviewed and approved in late September for matching funds for a Postdoctoral Fellowship.

Vancouver, British Columbia--(Newsfile Corp. - September 24, 2020) -  BTV-Business Television features opportunities in gold, a 20 minute COVID-19 test and cannabis therapy.

Toronto, Ontario--(Newsfile Corp. - September 23, 2020) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company, and its co-development partner, Orpheus Medica Inc. ("Orpheus") are pleased to announce they will be appearing on National TV on Saturday September 26 and Sunday September 27, 2020. The interview will focus on Therma's products and CoviSafeTM, a rapid test for detecting SARS-CoV-2 in saliva.

Toronto, Ontario--(Newsfile Corp. - September 15, 2020) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company, and its co-development partner, Orpheus Medica Inc. ("Orpheus") are pleased to provide an update on the development progress of the CoviSafeTM rapid test for detecting SARS-CoV-2 in saliva.

VANCOUVER, BC, Sept. 3, 2020 /CNW/ - Trading resumes in:

Toronto, Ontario--(Newsfile Corp. - September 3, 2020) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company, is pleased to announce that its co-development partner, Orpheus Medica Inc. ("Orpheus") has identified a series of polypeptides for the screening and detection of the virus (SARS-CoV-2) causing COVID-19.

VANCOUVER, BC, Sept. 3, 2020 /CNW/ - The following issues have been halted by IIROC:

VANCOUVER, BC, Sept. 1, 2020 /CNW/ - Trading resumes in:

Toronto, Ontario--(Newsfile Corp. - September 1, 2020) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company, provides updates on the following:

VANCOUVER, BC, Sept. 1, 2020 /CNW/ - The following issues have been halted by IIROC:

VANCOUVER, BC, Aug. 27, 2020 /CNW/ - Trading resumes in:

Toronto, Ontario--(Newsfile Corp. - August 27, 2020) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company, is pleased to announce that it has signed a co-development definitive agreement with Orpheus Medica Inc. ("Orpheus") or (Therma & Orpheus, the "Parties"). This agreement will allow Therma access to Orpheus' novel biological platform and the joint development of a rapid saliva test for the screening and detection of the virus (SARS-CoV-2) causing COVID-19.

VANCOUVER, BC, Aug. 27, 2020 /CNW/ - The following issues have been halted by IIROC:

Toronto, Ontario--(Newsfile Corp. - August 26, 2020) - Therma Bright Inc. (TSXV: THRM), ("Therma Bright" or the "Company"), a progressive medical device technology company, is pleased to announce that it has closed the transaction to acquire Benepod® pain relief technology and other innovative medical device technology from Saringer Life Science Technologies Inc. ("Saringer" or "SLST Inc."). After completion of final negotiations, Therma acquired the Saringer assets in an all cash transaction for $425,000.

Toronto, Ontario--(Newsfile Corp. - August 20, 2020) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company, provides this corporate update in response to inquiries from shareholders.

Toronto, Ontario--(Newsfile Corp. - August 13, 2020) -  Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company, is pleased to announce that it has completed its Phase 1 due diligence on Orpheus Medica's ("Orpheus") platform technology and plan for the development of a rapid saliva test (CoviSafe™) for the detection of the virus (SARS-CoV-2) causing COVID-19. CoviSafe™ will integrate Orpheus' novel biologics and advanced computational platforms, coupled with third party device technology, to develop a reliable palm-sized rapid test for screening of COVID-19 virus in saliva.

Toronto, Ontario--(Newsfile Corp. - August 6, 2020) - Therma Bright Inc. (TSXV: THRM), ("Therma" or the "Company"), a progressive medical device technology company, announces that it has completed the closing of its non-brokered private placement (the "Offering") previously announced on July 20, 2020 and increased July 22, 2020. The Company has issued 16,666,667 units for gross proceeds of $1,250,000. No finder's fee was paid in conjunction with the Offering. All securities issued are subject to a four month hold period expiring December 6, 2020, in accordance with applicable securities laws and the policies of the TSX Venture Exchange.

VANCOUVER, BC, July 24, 2020 /CNW/ - Trading resumes in:

Toronto, Ontario--(Newsfile Corp. - July 24, 2020) - Therma Bright Inc. (TSXV: THRM), ("Therma" or the "Company"), at the request of IIROC, Therma Bright Inc. wishes to confirm that the Company's management is unaware of any material change in the Company's operations that would account for the recent increase in market activity.

VANCOUVER, BC, July 24, 2020 /CNW/ - The following issues have been halted by IIROC:

Toronto, Ontario--(Newsfile Corp. - July 22, 2020) -  Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company, is pleased to announce that further to its news release of July 20, 2020, it has received interest above the previously announced private placement of up to 13,333,334 units at a price of $0.075 per Unit for gross proceeds of up to $1,000,000. Accordingly, the Company intends to increase the amount to be raised under its non-brokered private placement offering to $1,250,000 (up to 16,666,667 Units), subject to TSX Venture Exchange approval. Each Unit will be comprised of one common share of the Company and one-half (0.5) of one common share purchase warrant, and each whole warrant will be exercisable for one additional common share of the Company at a price of $0.15 for a period of 6 months from the closing date of the private placement. All other terms of the offering remain as set out in the Company's July 20, 2020 news release.

Toronto, Ontario--(Newsfile Corp. - July 20, 2020) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company, is pleased to announce that it proposes to undertake a non-brokered private placement (the "Private Placement") of up to 13,333,334 units ("Units") at a price of $0.075 per Unit for proceeds of $1,000,000 if the Private Placement is fully subscribed.

Toronto, Ontario--(Newsfile Corp. - July 16, 2020) - Therma Bright Inc. (TSXV: THRM), ("Therma" or the "Company"), a progressive medical device technology company, is pleased to provide an update on its project with Orpheus Medica to develop a rapid test to detect COVID-19 virus in saliva - the CoviSafeTM.

Toronto, Ontario--(Newsfile Corp. - July 9, 2020) - Therma Bright Inc. (TSXV: THRM), ("Therma Bright" or the "Company"), a progressive medical device technology company, is pleased to announce that it has completed due diligence and will move forward with closing of the asset purchase transaction with Saringer Life Science Technologies Inc. ("Saringer"). As previously reported on January 15, 2020 and April 8th, 2020, the Company entered a non-binding letter of intent ("LOI") to acquire Benepod® pain relief technology and other medical device related technology from Saringer. The terms as outlined in the press release issued on January 15, 2020 will remain the same in the definitive agreement.

Toronto, Ontario--(Newsfile Corp. - July 7, 2020) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company, is pleased to announce that it has entered into a binding letter of intent with Orpheus Medica Inc. ("Orpheus") to partner in the development of a rapid saliva test for the detection of the virus (SARS-CoV-2) causing COVID-19. Therma will provide funding for the project in phases ("Phase" or "Phases") as certain milestones are achieved and will provide medical device expertise to support accelerating the development of the rapid COVID-19 screening test to address the ongoing pandemic situation.

Toronto, Ontario--(Newsfile Corp. - May 11, 2020) -  Therma Bright Inc. (TSXV: THRM), ("Therma Bright" or the "Company"), a progressive medical device technology company, has initiated due diligence and has applied for government grants to manufacture personal protective equipment ("PPE") and hand sanitizers to combat the Covid-19 crisis. Several potential partners have approached Therma Bright to produce PPE and hand sanitizers for the Canadian and export markets. Therma Bright is ideally positioned to manufacture PPE leveraging the Company's quality management system ISO 13485 and recently approved MDSAP through SGS International. The Company also holds Health Canada & FDA approvals for its existing products and intends to utilize this regulatory expertise to apply to Health Canada for licenses related to PPE & hand sanitizers. Certain regulatory approvals are required to produce masks with specific claims such as filtering to N95 standards and hand sanitizers that claim to kill bacteria and viruses.

Toronto, Ontario--(Newsfile Corp. - April 8, 2020) - Therma Bright Inc. (TSXV: THRM), ("Therma Bright" or the "Company"), a progressive medical device technology company, has agreed to extend the closing of the asset purchase transaction with Saringer Life Science Technologies Inc. ("Saringer"). As previously reported on January 15, 2020 the Company entered into a non-binding letter of intent ("LOI") to acquire Benepod® pain relief technology and other medical device related technology from Saringer.

Toronto, Ontario--(Newsfile Corp. - January 15, 2020) - Therma Bright Inc. (TSXV: THRM), ("Therma Bright" or the "Company"), a progressive medical device technology company, enters into a non-binding letter of intent ("LOI") to acquire Benepod® pain relief technology and other medical device related technology from Saringer Life Science Technologies Inc. ("Saringer" or "SLST Inc."). Therma is in the process of conducting due diligence on Saringer. The LOI contemplates that this transaction will be structured as an asset purchase transaction which is expected to include the following terms:

Toronto, Ontario--(Newsfile Corp. - September 5, 2019) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company, today announces that the TherOZap™ technology under the Company's former name, The Jenex Corporation, has filed an international patent application under the PCT convention for its thermal therapy TherOZap™ and has recently entered the national phases in the US, Europe and Canada. In the international phase, the international search report found all searched claims to be novel. In the national phases, the claims will be further examined for patentability and allowance is expected. Therma is in the process of changing the international patent application name to: Therma Bright Inc. from the former name, The Jenex Corporation.

Toronto, Ontario--(Newsfile Corp. - September 4, 2019) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company, today announces that the TherOZap™ Technology proves successful at inhibiting the Zika virus during in-vitro tests.

Toronto, Ontario--(Newsfile Corp. - July 3, 2019) - Therma Bright Inc. (TSXV: THRM), ("Therma Bright" or the "Company"), a progressive medical device technology company, is pleased to announce that further to its press releases on October 11th and December 17th, 2018 and March 28th, 2019 that the Company continues testing of the TherOZap™ technology against the Zika virus upon the advice of one of the top research laboratories in Canada working with Therma Bright. A number of additional testing parameters have been added to the testing regime and, as previously reported, the aim of the research lab is to produce statistically relevant results. Therma Bright will report further information as it becomes available.

Toronto, Ontario--(Newsfile Corp. - March 28, 2019) - Therma Bright Inc. (TSXV: THRM), ("Therma Bright" or the "Company"), a progressive medical device technology company is pleased to announce, further to the press releases on October 11th and December 17th, 2018, that the Company is in the final stages of in vitro testing and awaits the results of the TherOZap™ technology against the Zika virus. Testing is being conducted through a top research laboratory in Canada. The Company expects to report further information as it becomes available.

Toronto, Ontario--(Newsfile Corp. - December 18, 2018) - Therma Bright Inc. (TSXV: THRM), ("Therma Bright" or the "Company"), a progressive medical device technology company, today announces that it has received the prototype of its pain relief device and provides an update on its TherOZap™ technology.

via NetworkWire - Therma Bright Inc. (TSXV: THRM), a medical device technology provider that delivers effective, non-invasive, pain free skin care through its proprietary technology powered by the company’s core technology, which is approved by the...

Toronto, Ontario--(Newsfile Corp. - November 7, 2018) - Icon Exploration Inc. (TSXV: IEX.H) ("Icon" or the "Company") is pleased to advise that it has now signed the formal share exchange agreement relating to its proposed change of business resulting from the acquisition of City View Green (the "Proposed Transaction").

Toronto, Ontario--(Newsfile Corp. - November 1, 2018) - Therma Bright Inc. (TSXV: THRM) ("Therma Bright" or the "Company"), a progressive medical device technology company announces that it will incorporate a 100% wholly owned subsidiary (the "Subsidiary") to hold device related technology for the application or use of medicinal or recreational marijuana. The Company plans to hold the pain relief device, as described in a press release on October 1st, and all related intellectual property developed for the pain relief device, in the Subsidiary. The pain relief device will incorporate the Company's thermal therapy technology and use pain relief formulations with medicinal cannabis and non-medicinal formulations in the form of creams, gels or salves. All research and administration of any medicinal cannabis will be dealt with through authorized and licensed research facilities.

Toronto, Ontario--(Newsfile Corp. - October 11, 2018) - Therma Bright Inc. (TSXV: THRM), ("Therma Bright" or the "Company"), a progressive medical device technology company announces, further to its press release on January 8, 2018 outlining results indicating effectiveness of its TherOZap™ technology at inhibiting the Zika virus, that the Company has engaged a top research laboratory made up of virology experts to further test the TherOZap™ technology against the Zika virus. The research group collaborates with and has access to other virology research experts around the world.

Toronto, Ontario--(Newsfile Corp. - October 1, 2018) - Therma Bright Inc. (TSXV: THRM), ("Therma Bright" or the "Company"), a progressive medical device technology company, provides the following updates:

Toronto, Ontario--(Newsfile Corp. - September 17, 2018) - Therma Bright Inc. (TSXV: THRM), ("Therma Bright", "Therma", or the "Company"- formerly The Jenex Corporation), a progressive medical device technology company, today is pleased to announce the appointment of Dr. Too Jae Min, Professor, Department of Anesthesiology and Pain Medicine, Korea University.

Toronto, Ontario--(Newsfile Corp. - July 11, 2018) - Therma Bright Inc. (TSXV: THRM), ("Therma Bright" or the "Company"), a progressive medical device technology company, announces that it has now completed the second and final tranche closing of its equity private placement initially announced on April 19, 2018 and has issued 580,000 units. No finder's fee was paid with respect to this tranche closing. All securities issued in this second tranche closing are subject to a hold period expiring four months plus a day after the date of their issuance.

Toronto, Ontario--(Newsfile Corp. - July 6, 2018) - Therma Bright Inc. (TSXV: THRM) ("Therma Bright" or the "Company"), a progressive medical device technology company, is pleased to announce the appointment of Victor Hugo as Chief Financial Officer (CFO) effective immediately.

Toronto, Ontario--(Newsfile Corp. - June 19, 2018) - Therma Bright Inc. (TSXV: THRM) ("Therma Bright" or the "Company"), a progressive medical device technology company, today is pleased to announce the appointment of Spencer Sung Bum Huh as Director.

Toronto, Ontario--(Newsfile Corp. - June 11, 2018) - Therma Bright Inc. (TSXV: THRM), ("Therma Bright" or the "Company"), a progressive medical device technology company, announces that it is extending the closing date of its previously announced equity financing of up to $2.5 million and convertible debenture financing of up to $1.5 million, for a further thirty (30) days from the date of this release. This extension will provide investors additional time to complete and deliver their subscriptions for the 2nd tranche closing of these financings (the 1st tranche closing having been press released on April 27, 2018). The Company intends the 2nd tranche closing to be completed as soon as possible within the next 30 days.

Toronto, Ontario--(Newsfile Corp. - May 10, 2018) - Therma Bright Inc. (TSXV: THRM) ("Therma Bright" or the "Company"), a progressive medical device technology company, announces that it will extend the closing date of its previously announced equity financing of up to $2.5 million and convertible debenture financing of up to $1.5 million, for up to thirty (30) days from the date of this release. This extension will provide investors additional time to complete and deliver their subscriptions for the 2nd tranche closing of these financings (the 1st tranche closing having been press released on April 27, 2018). The 2nd tranche will close as soon as possible, but in no event shall these financings remain open beyond June 9, 2018.

Toronto, Ontario--(Newsfile Corp. - May 8, 2018) - Therma Bright Inc. (TSXV: THRM), ("Therma Bright", "Therma", or the "Company"- formerly The Jenex Corporation), a progressive medical device technology company, today is pleased to announce that it intends to conduct research into the use of its thermal therapy technology with CBD and THC. Therma Bright will conduct research in conjunction with well-known pain relief research labs and clinics. Therma proposes to collaborate with pain relief research groups to develop a trademarked/patented thermal therapy device or devices for relief of; back pain, arthritis pain and other orthopedic based pain utilizing CBD and THC. All research and handling of any medical CBD or THC will be dealt with through authorized and licensed research facilities. Therma will provide further updates when formal arrangements have been made in regards to this research.

Toronto, Ontario--(Newsfile Corp. - April 27, 2018) - Therma Bright Inc. (TSXV: THRM), ("Therma Bright" or the "Company"), a progressive medical device technology company, announces that it has now completed a first tranche closing of its equity private placement previously announced April 19, 2018 and has issued 6,000,000 units at a price of $0.05/units for total proceeds of $300,000.

Toronto, Ontario--(Newsfile Corp. - April 19, 2018) - Therma Bright Inc. (TSXV: THRM), ("Therma Bright" or the "Company"), a progressive medical device technology company, provides the following updates:

Toronto, Ontario--(Newsfile Corp. - April 3, 2018) - Therma Bright Inc. (TSXV: THRM) ("Therma Bright" or the "Company"), a progressive medical device technology company, announces that further to its news releases on March 14, 2018 the Company has agreed to amend the definitive asset purchase agreement (the "Agreement') with the ICTV Brands group of companies, including ICTV Brands, Inc., pursuant to which it has agreed to acquire from the sellers the ClearTouch® nail phototherapy device (the "Nail Product") and the no!no! skin® phototherapy acne device (the "Acne Product", and together with the Nail Product, the "Purchased Products"), together with certain assets relating to the Purchased Products, but excluding any liabilities related thereto. The Purchased Products do not include any rights to the trademark or name "no!no!" or "no!no! skin". This transaction is an arm's length transaction.

Toronto, Ontario--(Newsfile Corp. - March 14, 2018) - Therma Bright Inc. (TSXV: THRM), ("Therma Bright" or the "Company"), a progressive medical device technology company, today is pleased to announce that further to its news releases on November 2, 2017, December 12, 2017, January 30, 2018 and March 1, 2018, the Company has now executed a definitive asset purchase agreement (the "Agreement') with the ICTV Brands group of companies, including ICTV Brands, Inc. (OTC-QX:ICTV), pursuant to which it has agreed to acquire from the sellers the ClearTouch® nail phototherapy device (the "Nail Product") and the no!no! skin® phototherapy acne device (the "Acne Product", and together with the Nail Product, the "Purchased Products"), together with certain assets relating to the Purchased Products, but excluding any liabilities related thereto. The Purchased Products do not include any rights to the trademark or name "no!no!" or "no!no! skin".

Toronto, Ontario--(Newsfile Corp. - March 2, 2018) - Therma Bright Inc. (TSXV: THRM), ("Therma Bright" or the "Company"), a progressive medical device technology company, today is pleased to announce that further to its news releases on November 2, 2017, December 12, 2017 and January 30, 2018, the Company has now finalized negotiations with the vendor and is awaiting regulatory approval for the proposed acquisition of assets that include a consumer medical device for acne and other cosmetic applications that encompass both heat and light therapy. (the "Proposed Acquisitions"). Therma Bright has agreed with the vendor on the final terms of the definitive asset purchase agreement ("APA") for of the Proposed Acquisitions and has made application to the TSX Venture Exchange for approval of this transaction. Closing will occur once regulatory approval is received and upon completion of a financing. The Company intends to finance the initial purchase price payment required under the APA through debt, equity or a combination thereof with terms of such financing to be announced before closing.

Toronto, Ontario--(Newsfile Corp. - February 16, 2018) - Therma Bright Inc. (TSXV: THRM) ("Therma Bright" or the "Company"), a progressive medical device technology company, announces that further to its news release of January 17, 2018, it has now completed certain debt settlement transactions and issued an aggregate of 2,445,150 common shares to settle an aggregate of $244,515 debt.